- Trials with a EudraCT protocol (143)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)
143 result(s) found for: Palatability.
Displaying page 8 of 8.
EudraCT Number: 2019-003696-19 | Sponsor Protocol Number: E7080-G000-230 | Start Date*: 2020-02-28 | |||||||||||
Sponsor Name:Eisai Ltd | |||||||||||||
Full Title: A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adoles... | |||||||||||||
Medical condition: Relapsed or Refractory Osteosarcoma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) FR (Completed) BE (Completed) IE (Completed) NL (Completed) IT (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002375-34 | Sponsor Protocol Number: EFC15299 | Start Date*: 2020-07-23 | ||||||||||||||||
Sponsor Name:Genzyme Corporation | ||||||||||||||||||
Full Title: A multicenter, multinational, randomized, double-blind, placebo-controlled study to assess the efficacy, pharmacodynamics, pharmacokinetics, safety, and tolerability of venglustat in late-onset GM2... | ||||||||||||||||||
Medical condition: Tay-Sachs disease Sandhoff disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Prematurely Ended) AT (Completed) FR (Completed) ES (Completed) CZ (Prematurely Ended) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000212-28 | Sponsor Protocol Number: LOXO-RET-18036 | Start Date*: 2020-04-15 | ||||||||||||||||||||||||||
Sponsor Name:Loxo Oncology, Inc. | ||||||||||||||||||||||||||||
Full Title: A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors | ||||||||||||||||||||||||||||
Medical condition: Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
